1. Home
  2. LSF vs GRDX Comparison

LSF vs GRDX Comparison

Compare LSF & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

HOLD

Current Price

$4.55

Market Cap

48.0M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.16

Market Cap

39.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LSF
GRDX
Founded
2015
N/A
Country
United States
United Kingdom
Employees
28
2
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.0M
39.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LSF
GRDX
Price
$4.55
$4.16
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
78.2K
76.2K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
75.28
N/A
EPS
0.11
N/A
Revenue
$49,889,286.00
N/A
Revenue This Year
$90.82
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$39.64
N/A
Revenue Growth
15.23
N/A
52 Week Low
$1.96
$1.87
52 Week High
$7.80
$6.93

Technical Indicators

Market Signals
Indicator
LSF
GRDX
Relative Strength Index (RSI) 57.25 44.88
Support Level $2.23 $2.01
Resistance Level $5.11 $5.30
Average True Range (ATR) 0.41 0.47
MACD -0.07 -0.09
Stochastic Oscillator 41.25 19.16

Price Performance

Historical Comparison
LSF
GRDX

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: